![](https://i.imgur.com/CLvY2jA.png")
Novavax (NASDAQ:NVAX) CEO Stanley Erck said that his company's COVID vaccine has benefits over mRNA vaccines that could provide competitive advantages.
Speaking on CNBC's Squawk on the Street, Erck emphasized that the vaccine has effectiveness against multiple COVID variants, including Omicron.
"When you look at our profile vs. some of the others, we have a much more benign profile than the others so it has very few side effects," he said.
Erck added that the vaccine needs to be kept at normal refrigerator temperatures, as opposed to the Pfizer (PFE -0.6%)/BioNTech (BNTX -2.0%) and Moderna (MRNA -1.5%) shots, which need to be kept at much colder temperatures.
He noted that due to the vaccine's mechanism of action, it wouldn't take long to develop a vaccine that would work specifically against Omicron or any other future variant.
https://seekingalpha.com/news/3783039-ce...shots-cnbc
Speaking on CNBC's Squawk on the Street, Erck emphasized that the vaccine has effectiveness against multiple COVID variants, including Omicron.
"When you look at our profile vs. some of the others, we have a much more benign profile than the others so it has very few side effects," he said.
Erck added that the vaccine needs to be kept at normal refrigerator temperatures, as opposed to the Pfizer (PFE -0.6%)/BioNTech (BNTX -2.0%) and Moderna (MRNA -1.5%) shots, which need to be kept at much colder temperatures.
He noted that due to the vaccine's mechanism of action, it wouldn't take long to develop a vaccine that would work specifically against Omicron or any other future variant.
https://seekingalpha.com/news/3783039-ce...shots-cnbc
